Kong Heng Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kong Heng Lee has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ching Soong Khoo
Department of Medicine, Faculty of Medicine Universiti Kebangsaan Malaysia Kuala Lumpur Malaysia
2 shared publications Hui Jan Tan
Department of Medicine, Faculty of Medicine Universiti Kebangsaan Malaysia Kuala Lumpur Malaysia
2 shared publications- Carmen Jia Yinn Chang
Department of Medicine, Faculty of Medicine Universiti Kebangsaan Malaysia Kuala Lumpur Malaysia
1 shared publication - Eugen Trinka
Department of Neurology, Neurocritical Care, and Neurorehabilitation, Center for Cognitive Neuroscience, Member of European Reference Network EpiCARE Christian Doppler University Hospital, Paracelsus Medical University Salzburg Austria
1 shared publication - Hazlina Mahadzir
Department of Medicine, Faculty of Medicine Universiti Kebangsaan Malaysia Kuala Lumpur Malaysia
1 shared publication Hui Xin Oh
Department of Medicine, Faculty of Medicine Universiti Kebangsaan Malaysia Kuala Lumpur Malaysia
1 shared publication
Latest Publications
- 15 August 2026
- Published by Wiley in Neurology and Clinical Neuroscience
The Potential Role of Amyloid Precursor Protein Fragments as a Screening Tool for Mild Cognitive Impairment
Background: Mild cognitive impairment (MCI) is a transitional stage between normal aging and dementia, in which early detection is essential. Urinary amyloid precursor protein (APP) fragments have been proposed as a non‐invasive biomarker, but their diagnostic value in elderly populations remains uncertain. This study evaluated the diagnostic performance of urinary APP fragments, particularly amyloid‐β protein precursor (AβPP), for MCI screening and examined associated sociodemographic and clinical risk factors among adults aged ≥ 65 years. Methods: A single‐center, cross‐sectional, case–control study was conducted at Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia. A total of 140 age‐ and gender‐matched participants were recruited (70 MCI, 70 cognitively normal). Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA). Urinary AβPP was measured using a lateral flow immunochromatography kit. Data on comorbidities, body mass index, education level and smoking status were collected. Diagnostic accuracy and logistic regression analyses were performed. Results: The urinary AβPP test showed a sensitivity of 74.3%, specificity of 27.1%, and overall accuracy of 50.7%, with no significant association with cognitive status ( p = 0.424). Diabetes mellitus was an independent risk factor predictor for MCI ( p = 0.007, OR = 5.764, 95% CI 1.615–20.572) along with age ( p = 0.001, OR = 1.638, 95% CI 1.234–2.175). Conclusion: Urinary AβPP shows high sensitivity but low specificity for MCI screening. Diabetes mellitus is a significant predictor of MCI, highlighting the role of metabolic health in early cognitive decline.
- 15 August 2026
- Published by Wiley in Neurology and Clinical Neuroscience
The Potential Role of Amyloid Precursor Protein Fragments as a Screening Tool for Mild Cognitive Impairment
Background: Mild cognitive impairment (MCI) is a transitional stage between normal aging and dementia, in which early detection is essential. Urinary amyloid precursor protein (APP) fragments have been proposed as a non‐invasive biomarker, but their diagnostic value in elderly populations remains uncertain. This study evaluated the diagnostic performance of urinary APP fragments, particularly amyloid‐β protein precursor (AβPP), for MCI screening and examined associated sociodemographic and clinical risk factors among adults aged ≥ 65 years. Methods: A single‐center, cross‐sectional, case–control study was conducted at Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia. A total of 140 age‐ and gender‐matched participants were recruited (70 MCI, 70 cognitively normal). Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA). Urinary AβPP was measured using a lateral flow immunochromatography kit. Data on comorbidities, body mass index, education level and smoking status were collected. Diagnostic accuracy and logistic regression analyses were performed. Results: The urinary AβPP test showed a sensitivity of 74.3%, specificity of 27.1%, and overall accuracy of 50.7%, with no significant association with cognitive status ( p = 0.424). Diabetes mellitus was an independent risk factor predictor for MCI ( p = 0.007, OR = 5.764, 95% CI 1.615–20.572) along with age ( p = 0.001, OR = 1.638, 95% CI 1.234–2.175). Conclusion: Urinary AβPP shows high sensitivity but low specificity for MCI screening. Diabetes mellitus is a significant predictor of MCI, highlighting the role of metabolic health in early cognitive decline.
- Open Access
- 28 January 2025
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 18
The use of cannabidiol as adjunctive therapy in adult patients with drug-resistant epilepsy: a systematic review and meta-analysis
Background: Highly purified cannabidiol (CBD), recently approved for various neurological disorders, is explored as a potential therapeutic avenue for drug-resistant epilepsy (DRE) among adult people with epilepsy (PWE) in this systematic review and meta-analysis. Objectives: To conduct an extensive literature review and meta-analysis of CBD use for DRE in adult PWE. Design: Systematic review and meta-analysis. Data sources and methods: We conducted a systematic review of the literature according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and two electronic resources; we searched Ovid MEDLINE and Scopus using appropriate keywords until August 2023. Data were presented as standardized mean difference (SMD) and odds ratio with confidence interval (CI) via random effect. We appraised the risk of bias of the included studies using the Joanna Briggs Institute critical appraisal tool while their strength of evidence with the Oxford Centre for Evidence-Based Medicine (OCEBM) and Grading of Recommendations Assessment Development and Education (GRADE) Levels of Evidence. Results: We identified 16 studies, 3 of which were randomized controlled trials and 3 prospective cohort studies, while the rest were expanded access programs, deriving a total of 668 participants receiving CBD for seizure control. CBD was used concomitantly with antiseizure medications in all studies. There was a reduction in seizures in the group receiving CBD therapy compared to the placebo group [SMD: −1.50, 95% CI (−3.47, 0.47)], though this did not reach statistical significance. Conclusion: The evidence on CBD use in adult patients with DRE demonstrates a moderate level of certainty according to GRADE level and OCEBM level 2. Further prospective studies involving multiple centers are encouraged to study both the efficacy and safety of CBD in adult patients with DRE. Trial registration: International Prospective Register of Systematic Reviews (PROSPERO) 2023 CRD42023449955.
- 28 January 2025
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 18
Open AccessThe use of cannabidiol as adjunctive therapy in adult patients with drug-resistant epilepsy: a systematic review and meta-analysis
Background: Highly purified cannabidiol (CBD), recently approved for various neurological disorders, is explored as a potential therapeutic avenue for drug-resistant epilepsy (DRE) among adult people with epilepsy (PWE) in this systematic review and meta-analysis. Objectives: To conduct an extensive literature review and meta-analysis of CBD use for DRE in adult PWE. Design: Systematic review and meta-analysis. Data sources and methods: We conducted a systematic review of the literature according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and two electronic resources; we searched Ovid MEDLINE and Scopus using appropriate keywords until August 2023. Data were presented as standardized mean difference (SMD) and odds ratio with confidence interval (CI) via random effect. We appraised the risk of bias of the included studies using the Joanna Briggs Institute critical appraisal tool while their strength of evidence with the Oxford Centre for Evidence-Based Medicine (OCEBM) and Grading of Recommendations Assessment Development and Education (GRADE) Levels of Evidence. Results: We identified 16 studies, 3 of which were randomized controlled trials and 3 prospective cohort studies, while the rest were expanded access programs, deriving a total of 668 participants receiving CBD for seizure control. CBD was used concomitantly with antiseizure medications in all studies. There was a reduction in seizures in the group receiving CBD therapy compared to the placebo group [SMD: −1.50, 95% CI (−3.47, 0.47)], though this did not reach statistical significance. Conclusion: The evidence on CBD use in adult patients with DRE demonstrates a moderate level of certainty according to GRADE level and OCEBM level 2. Further prospective studies involving multiple centers are encouraged to study both the efficacy and safety of CBD in adult patients with DRE. Trial registration: International Prospective Register of Systematic Reviews (PROSPERO) 2023 CRD42023449955.